세계의 비침습적 산전검사 시장(2025-2035년) : 산업 분석, 시장 규모, 점유율, 성장, 동향, 예측

Non-invasive Prenatal Testing Market - Scope of Report

TMR's report on the global non-invasive prenatal testing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global non-invasive prenatal testing market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-invasive prenatal testing market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the non-invasive prenatal testing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-invasive prenatal testing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-invasive prenatal testing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-invasive prenatal testing market.

The report delves into the competitive landscape of the global non-invasive prenatal testing market. Key players operating in the global non-invasive prenatal testing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-invasive prenatal testing market profiled in this report.

Key Questions Answered in Global non-invasive prenatal testing Market Report:

• What is the sales/revenue generated by non-invasive prenatal testing across all regions during the forecast period?
• What are the opportunities in the global non-invasive prenatal testing market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Non-invasive Prenatal Testing Market - Research Objectives and Research Approach

The comprehensive report on the global non-invasive prenatal testing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global non-invasive prenatal testing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-invasive prenatal testing market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Non-invasive Prenatal Testing Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, 2020 to 2035

5. Key Insights

• 5.1. Technological Advancements
• 5.2. Pricing Trends
• 5.3. Regulatory Landscape across Key Regions / Countries
• 5.4. PORTER's Five Forces Analysis
• 5.5. PESTEL Analysis
• 5.6. Value Chain Analysis
• 5.7. Key Purchase Metrics for End-users
• 5.8. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions, funding and investments)
• 5.9. Benchmarking of the Product Offered by the Competitors

6. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Test Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Test Type, 2020 to 2035
  • 6.3.1. Cell-Free DNA Screening Test
  • 6.3.2. Serum Marker Screening Test
  • 6.3.3. Neural Tube Defects Test
  • 6.3.4. Ultrasonography
• 6.4. Market Attractiveness By Test Type

7. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Product

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Product, 2020 to 2035
  • 7.3.1. Instruments
  • 7.3.2. Kits & Reagents
• 7.4. Market Attractiveness By Product

8. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Technology

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Technology, 2020 to 2035
  • 8.3.1. Whole-Genome Sequencing
  • 8.3.2. SNP Analysis
  • 8.3.3. Microarray Analysis
  • 8.3.4. Rolling Circle Amplification
• 8.4. Market Attractiveness By Technology

9. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Indication

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By Indication, 2020 to 2035
  • 9.3.1. Down Syndrome (trisomy 21)
  • 9.3.2. Edwards syndrome (trisomy 18)
  • 9.3.3. Patau syndrome (trisomy 13)
  • 9.3.4. Turner Syndrom (Monosomy X/XO)
  • 9.3.5. Klinefelter Syndrome (XXY)
  • 9.3.6. Jacob's Syndrome (XYY)
  • 9.3.7. Gender Identification
  • 9.3.8. Others (Triple X, etc.)
• 9.4. Market Attractiveness By Indication

10. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By End-user

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast By End-user, 2020 to 2035
  • 10.3.1. Hospitals
  • 10.3.2. Specialty Clinics
  • 10.3.3. Diagnostics Laboratories
  • 10.3.4. Others (Research Institutes, etc.)
• 10.4. Market Attractiveness By End-user

11. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Region

• 11.1. Key Findings
• 11.2. Market Value Forecast By Region
  • 11.2.1. North America
  • 11.2.2. Europe
  • 11.2.3. Asia Pacific
  • 11.2.4. Latin America
  • 11.2.5. Middle East & Africa
• 11.3. Market Attractiveness By Region

12. North America Non-invasive Prenatal Testing Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Test Type, 2020 to 2035
  • 12.2.1. Cell-Free DNA Screening Test
  • 12.2.2. Serum Marker Screening Test
  • 12.2.3. Neural Tube Defects Test
  • 12.2.4. Ultrasonography
• 12.3. Market Value Forecast By Product, 2020 to 2035
  • 12.3.1. Instruments
  • 12.3.2. Kits & Reagents
• 12.4. Market Value Forecast By Technology, 2020 to 2035
  • 12.4.1. Whole-Genome Sequencing
  • 12.4.2. SNP Analysis
  • 12.4.3. Microarray Analysis
  • 12.4.4. Rolling Circle Amplification
• 12.5. Market Value Forecast By Indication, 2020 to 2035
  • 12.5.1. Down Syndrome (trisomy 21)
  • 12.5.2. Edwards syndrome (trisomy 18)
  • 12.5.3. Patau syndrome (trisomy 13)
  • 12.5.4. Turner Syndrom (Monosomy X/XO)
  • 12.5.5. Klinefelter Syndrome (XXY)
  • 12.5.6. Jacob's Syndrome (XYY)
  • 12.5.7. Gender Identification
  • 12.5.8. Others (Triple X, etc.)
• 12.6. Market Value Forecast By End-user, 2020 to 2035
  • 12.6.1. Hospitals
  • 12.6.2. Specialty Clinics
  • 12.6.3. Diagnostics Laboratories
  • 12.6.4. Others (Research Institutes, etc.)
• 12.7. Market Value Forecast By Country, 2020 to 2035
  • 12.7.1. U.S.
  • 12.7.2. Canada
• 12.8. Market Attractiveness Analysis
  • 12.8.1. By Test Type
  • 12.8.2. By Product
  • 12.8.3. By Technology
  • 12.8.4. By Indication
  • 12.8.5. By End-user
  • 12.8.6. By Country

13. Europe Non-invasive Prenatal Testing Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Test Type, 2020 to 2035
  • 13.2.1. Cell-Free DNA Screening Test
  • 13.2.2. Serum Marker Screening Test
  • 13.2.3. Neural Tube Defects Test
  • 13.2.4. Ultrasonography
• 13.3. Market Value Forecast By Product, 2020 to 2035
  • 13.3.1. Instruments
  • 13.3.2. Kits & Reagents
• 13.4. Market Value Forecast By Technology, 2020 to 2035
  • 13.4.1. Whole-Genome Sequencing
  • 13.4.2. SNP Analysis
  • 13.4.3. Microarray Analysis
  • 13.4.4. Rolling Circle Amplification
• 13.5. Market Value Forecast By Indication, 2020 to 2035
  • 13.5.1. Down Syndrome (trisomy 21)
  • 13.5.2. Edwards syndrome (trisomy 18)
  • 13.5.3. Patau syndrome (trisomy 13)
  • 13.5.4. Turner Syndrom (Monosomy X/XO)
  • 13.5.5. Klinefelter Syndrome (XXY)
  • 13.5.6. Jacob's Syndrome (XYY)
  • 13.5.7. Gender Identification
  • 13.5.8. Others (Triple X, etc.)
• 13.6. Market Value Forecast By End-user ,2020 to 2035
  • 13.6.1. Hospitals
  • 13.6.2. Specialty Clinics
  • 13.6.3. Diagnostics Laboratories
  • 13.6.4. Others (Research Institutes, etc.)
• 13.7. Market Value Forecast By Country/Sub-region ,2020 to 2035
  • 13.7.1. Germany
  • 13.7.2. U.K.
  • 13.7.3. France
  • 13.7.4. Italy
  • 13.7.5. Spain
  • 13.7.6. Rest of Europe
• 13.8. Market Attractiveness Analysis
  • 13.8.1. By Test Type
  • 13.8.2. By Product
  • 13.8.3. By Technology
  • 13.8.4. By Indication
  • 13.8.5. By End-user
  • 13.8.6. By Country/Sub-region

14. Asia Pacific Non-invasive Prenatal Testing Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Test Type, 2020 to 2035
  • 14.2.1. Cell-Free DNA Screening Test
  • 14.2.2. Serum Marker Screening Test
  • 14.2.3. Neural Tube Defects Test
  • 14.2.4. Ultrasonography
• 14.3. Market Value Forecast By Product, 2020 to 2035
  • 14.3.1. Instruments
  • 14.3.2. Kits & Reagents
• 14.4. Market Value Forecast By Technology, 2020 to 2035
  • 14.4.1. Whole-Genome Sequencing
  • 14.4.2. SNP Analysis
  • 14.4.3. Microarray Analysis
  • 14.4.4. Rolling Circle Amplification
• 14.5. Market Value Forecast By Indication, 2020 to 2035
  • 14.5.1. Down Syndrome (trisomy 21)
  • 14.5.2. Edwards syndrome (trisomy 18)
  • 14.5.3. Patau syndrome (trisomy 13)
  • 14.5.4. Turner Syndrom (Monosomy X/XO)
  • 14.5.5. Klinefelter Syndrome (XXY)
  • 14.5.6. Jacob's Syndrome (XYY)
  • 14.5.7. Gender Identification
  • 14.5.8. Others (Triple X, etc.)
• 14.6. Market Value Forecast By End-user, 2020 to 2035
  • 14.6.1. Hospitals
  • 14.6.2. Specialty Clinics
  • 14.6.3. Diagnostics Laboratories
  • 14.6.4. Others (Research Institutes, etc.)
• 14.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 14.7.1. China
  • 14.7.2. India
  • 14.7.3. Japan
  • 14.7.4. Australia & New Zealand
  • 14.7.5. Rest of Asia Pacific
• 14.8. Market Attractiveness Analysis
  • 14.8.1. By Test Type
  • 14.8.2. By Product
  • 14.8.3. By Technology
  • 14.8.4. By Indication
  • 14.8.5. By End-user
  • 14.8.6. By Country/Sub-region

15. Latin America Non-invasive Prenatal Testing Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Test Type, 2020 to 2035
  • 15.2.1. Cell-Free DNA Screening Test
  • 15.2.2. Serum Marker Screening Test
  • 15.2.3. Neural Tube Defects Test
  • 15.2.4. Ultrasonography
• 15.3. Market Value Forecast By Product, 2020 to 2035
  • 15.3.1. Instruments
  • 15.3.2. Kits & Reagents
• 15.4. Market Value Forecast By Technology ,2020 to 2035
  • 15.4.1. Whole-Genome Sequencing
  • 15.4.2. SNP Analysis
  • 15.4.3. Microarray Analysis
  • 15.4.4. Rolling Circle Amplification
• 15.5. Market Value Forecast By Indication, 2020 to 2035
  • 15.5.1. Down Syndrome (trisomy 21)
  • 15.5.2. Edwards syndrome (trisomy 18)
  • 15.5.3. Patau syndrome (trisomy 13)
  • 15.5.4. Turner Syndrom (Monosomy X/XO)
  • 15.5.5. Klinefelter Syndrome (XXY)
  • 15.5.6. Jacob's Syndrome (XYY)
  • 15.5.7. Gender Identification
  • 15.5.8. Others (Triple X, etc.)
• 15.6. Market Value Forecast By End-user, 2020 to 2035
  • 15.6.1. Hospitals
  • 15.6.2. Specialty Clinics
  • 15.6.3. Diagnostics Laboratories
  • 15.6.4. Others (Research Institutes, etc.)
• 15.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 15.7.1. Brazil
  • 15.7.2. Mexico
  • 15.7.3. Rest of Latin America
• 15.8. Market Attractiveness Analysis
  • 15.8.1. By Test Type
  • 15.8.2. By Product
  • 15.8.3. By Technology
  • 15.8.4. By Indication
  • 15.8.5. By End-user
  • 15.8.6. By Country/Sub-region

16. Middle East & Africa Non-invasive Prenatal Testing Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast By Test Type, 2020 to 2035
  • 16.2.1. Cell-Free DNA Screening Test
  • 16.2.2. Serum Marker Screening Test
  • 16.2.3. Neural Tube Defects Test
  • 16.2.4. Ultrasonography
• 16.3. Market Value Forecast By Product, 2020 to 2035
  • 16.3.1. Instruments
  • 16.3.2. Kits & Reagents
• 16.4. Market Value Forecast By Technology, 2020 to 2035
  • 16.4.1. Whole-Genome Sequencing
  • 16.4.2. SNP Analysis
  • 16.4.3. Microarray Analysis
  • 16.4.4. Rolling Circle Amplification
• 16.5. Market Value Forecast By Indication, 2020 to 2035
  • 16.5.1. Down Syndrome (trisomy 21)
  • 16.5.2. Edwards syndrome (trisomy 18)
  • 16.5.3. Patau syndrome (trisomy 13)
  • 16.5.4. Turner Syndrom (Monosomy X/XO)
  • 16.5.5. Klinefelter Syndrome (XXY)
  • 16.5.6. Jacob's Syndrome (XYY)
  • 16.5.7. Gender Identification
  • 16.5.8. Others (Triple X, etc.)
• 16.6. Market Value Forecast By End-user, 2020 to 2035
  • 16.6.1. Hospitals
  • 16.6.2. Specialty Clinics
  • 16.6.3. Diagnostics Laboratories
  • 16.6.4. Others (Research Institutes, etc.)
• 16.7. Market Value Forecast By Country/Sub-region ,2020 to 2035
  • 16.7.1. GCC Countries
  • 16.7.2. South Africa
  • 16.7.3. Rest of Middle East & Africa
• 16.8. Market Attractiveness Analysis
  • 16.8.1. By Test Type
  • 16.8.2. By Product
  • 16.8.3. By Technology
  • 16.8.4. By Indication
  • 16.8.5. By End-user
  • 16.8.6. By Country/Sub-region

17. Competition Landscape

• 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 17.2. Market Share Analysis By Company (2024)
• 17.3. Company Profiles
  • 17.3.1. F. Hoffmann-La Roche Ltd
    • 17.3.1.1. Company Overview
    • 17.3.1.2. Financial Overview
    • 17.3.1.3. Product Portfolio
    • 17.3.1.4. Business Strategies
    • 17.3.1.5. Recent Developments
  • 17.3.2. Natera, Inc.
    • 17.3.2.1. Company Overview
    • 17.3.2.2. Financial Overview
    • 17.3.2.3. Product Portfolio
    • 17.3.2.4. Business Strategies
    • 17.3.2.5. Recent Developments
  • 17.3.3. Illumina, Inc
    • 17.3.3.1. Company Overview
    • 17.3.3.2. Financial Overview
    • 17.3.3.3. Product Portfolio
    • 17.3.3.4. Business Strategies
    • 17.3.3.5. Recent Developments
  • 17.3.4. PerkinElmer Inc.
    • 17.3.4.1. Company Overview
    • 17.3.4.2. Financial Overview
    • 17.3.4.3. Product Portfolio
    • 17.3.4.4. Business Strategies
    • 17.3.4.5. Recent Developments
  • 17.3.5. Eurofins LifeCodexx AG
    • 17.3.5.1. Company Overview
    • 17.3.5.2. Financial Overview
    • 17.3.5.3. Product Portfolio
    • 17.3.5.4. Business Strategies
    • 17.3.5.5. Recent Developments
  • 17.3.6. IGENOMIX
    • 17.3.6.1. Company Overview
    • 17.3.6.2. Financial Overview
    • 17.3.6.3. Product Portfolio
    • 17.3.6.4. Business Strategies
    • 17.3.6.5. Recent Developments
  • 17.3.7. Pacific Biosciences
    • 17.3.7.1. Company Overview
    • 17.3.7.2. Financial Overview
    • 17.3.7.3. Product Portfolio
    • 17.3.7.4. Business Strategies
    • 17.3.7.5. Recent Developments
  • 17.3.8. BGI
    • 17.3.8.1. Company Overview
    • 17.3.8.2. Financial Overview
    • 17.3.8.3. Product Portfolio
    • 17.3.8.4. Business Strategies
    • 17.3.8.5. Recent Developments
  • 17.3.9. Laboratory Corporation of America Holdings
    • 17.3.9.1. Company Overview
    • 17.3.9.2. Financial Overview
    • 17.3.9.3. Product Portfolio
    • 17.3.9.4. Business Strategies
    • 17.3.9.5. Recent Developments
  • 17.3.10. Agilent Technologies, Inc.
    • 17.3.10.1. Company Overview
    • 17.3.10.2. Financial Overview
    • 17.3.10.3. Product Portfolio
    • 17.3.10.4. Business Strategies
    • 17.3.10.5. Recent Developments
  • 17.3.11. Berry Genetics Inc.
    • 17.3.11.1. Company Overview
    • 17.3.11.2. Financial Overview
    • 17.3.11.3. Product Portfolio
    • 17.3.11.4. Business Strategies
    • 17.3.11.5. Recent Developments